Melanocortin pathway research peptide (MC3R/MC4R). 25+ peer-reviewed preclinical studies. 99%+ HPLC-verified purity. 3-lab independent COA on every batch.
PT-141 (Bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist that acts on MC3R and MC4R receptors in the central nervous system. It is the only melanocortin-pathway research peptide that acts on CNS receptors rather than the vascular system — a fundamental distinction from PDE5 inhibitor mechanisms.
Originally derived from the alpha-MSH peptide Melanotan-II, PT-141 was developed as a focused research tool for melanocortin signaling pathways. With 25+ publications, it has been studied in sexual function signaling, melanocortin pathway modulation, and central nervous system activation models.
PT-141 is classified as a research-use-only compound. It is not FDA-approved for any therapeutic indication in this form. All references below describe preclinical (in vitro or animal model) research contexts, not human clinical outcomes.
Studied in preclinical models examining melanocortin-mediated sexual response pathways. Unlike PDE5 inhibitors that act on vascular smooth muscle, PT-141 research focuses on central nervous system initiation of arousal signaling.
Preclinical studies examine PT-141's selective agonism at MC3R and MC4R receptor subtypes. Research explores downstream signaling cascades and receptor desensitization kinetics in CNS tissue models.
Research examines PT-141's mechanism of action through hypothalamic melanocortin circuits. Studies explore the distinction between central (CNS) and peripheral (vascular) signaling pathways in functional models.
Preclinical research explores PT-141's binding affinity profiles across melanocortin receptor subtypes (MC1R–MC5R) and its selectivity for MC3R/MC4R versus other subtypes in competitive binding assays.
Research-grade PT-141 (Bremelanotide) with 3-lab COA verification is available at SMART MD Peptides in a 10mg formulation. Every batch is publicly verifiable at smartmdpeptides.com/verify.
99%+ HPLC-verified purity across all PT-141 batches. Each batch is independently verified by 3 U.S. laboratories — HPLC for purity, mass spectrometry for molecular weight, and LAL endotoxin assay for safety.
PT-141 acts on melanocortin receptors (MC3R/MC4R) in the central nervous system, not on vascular smooth muscle like PDE5 inhibitors. This is a fundamentally different mechanism — CNS-initiated signaling rather than peripheral vasodilation.
PT-141 is legal to acquire for research purposes. It is classified as a research-use-only compound — not intended for human consumption in this form. Licensed researchers and physicians may acquire it for research protocols and practice-of-medicine use.
Lyophilized (unreconstituted) PT-141 should be stored at -20°C, protected from light. Once reconstituted, store at 2-8°C and use within the timeframe specified on your lot-specific documentation.
Check the COA before you buy. Compare it against any other supplier's documentation.